Our application note showcases the significant benefits of integrating CRISPR technology with CAR-T cell therapy, offering a promising approach to targeting cancer cells. With our optimized protocol for CAR knock-in in primary T cells, researchers can achieve higher efficiency and accuracy in their targeted knock-in, leading to improved outcomes in their cancer research development.
Please fill out the form below to access this informative application note and explore: